



Anti Viral Bacterial Biotechnology



AVB
BIOTECH

Summary Business Plan –
October 2023



Animal Health
Treatment and Distribution



Science and Technology
Financial Investments

About Us

- AVB Biotechnology Inc. was founded in 2020 with the aim of developing treatments to combat the COVID-19 pandemic.
- It is a domestic company that conducts research and development on numerous diseases, including infections, for which there is currently no effective treatment.
- AVB Biotech has achieved the invention of an effective Quantum Signal Treatment System for all types of viruses and bacterias and developed a medical device called Dr. Biolyse®.



AVB
BIOTECH




SCIENCE and TECHNOLOGY



Our Treatment Technology

A new invention: Quantum Signal Therapy

- «Quantum Signal Therapy» was developed by AVB Biotech® in 2020.
- It is a first in the world in the field of quantum biology.
- It first entered the literature in 2021.
- It was chosen as the best biotechnology invention of 2021.
- Between 2020 and 2023, it was proven in scientific studies that it is effective on all types of viruses and bacteria.
- It has started to be used for therapeutic purposes in animals in 2023.
- Before use for therapeutic purposes in humans, the clinical study process was initiated by designing treatment protocols on 6 strategic diseases for which there is no valid treatment.



Our Science Journey



Sepsis Animal Experiment

It was completed with 100% success.

2



Parvovirus Clinical Study

It was completed with 100% success.

4



Covid19 Clinical Study

Continues...

6

2020

1



Invitro Virus Simulation

It was completed with 100% success.

3



Feline Corona Virus Clinical Study

It was completed with 95% success.

5



Spinal Cord Paralysis Case Study

It was completed with 100% success.

2023

Some Scientific Studies

These 3 strategic studies include pre-human, pre-clinical and clinical levels.

Sepsis



It is the deadliest form of infection known as blood poisoning or hospital germ.

It was carried out in the independent laboratory environment by independent scientists.

In an animal experimental study conducted with a microorganism load that is 50 million times higher than normal infection, a 100% treatment effect was achieved.

Canine Parvovirus



It is the deadliest canine viral epidemic known as bloody diarrhea.

It is an official clinical study conducted on owned and real sick animals.

A 100% treatment effect was achieved on the disease with a mortality rate of over 80%.

Feline Corona Virus



It is the form of infection caused by the deadliest type of coronavirus known as FIP.

It is an official clinical study conducted on owned and real sick animals.

A 95% treatment effect was achieved on the disease with a mortality rate of over 90%.

Results

The effects and scope of treatment have been shown by scientific studies.

Effects Shown In Scientific Studies

Viruses

According to Genome Structure




RNA




DNA



According to Wall Structure



With Envelope



Without Envelope



Bacteria



Inflammation



Oxidative Stress



Fever



Apoptosis



Scope of Treatment

Primary Treatments

- Viral Diseases
- Bacterial Diseases

Animals



Humans




Other Treatments

- Anti-Inflammatory Treatment
- Fever Reducer
- Antioxidant
- Antiapoptotic
- Cellular Immune Support



Current Status


Baseline indicators according to commercial medicinal product standards and regulatory requirements



%90

Basic requirements are met.

Outside the CE and FDA regions, more than 100 countries conduct their own regulatory practices. However, in general, the completion of scientific stages and the adequacy of the quality system are fundamental worldwide.



%100

Basic requirements are met.
Treatment activities have started.



AVB
BIOTECH

**Development
Program**

Development Program

A development and investment program has been created in 3 main areas.

Science

Clinical study programs designed to demonstrate the therapeutic effects of QST on diseases without a valid treatment.

Investigation of the therapeutic and developmental effects of Quantum Tunneling Technique and signal coding beyond infectious diseases.



Technology

Improving usability ergonomics, completing wearable treatment technology, and integrating artificial intelligence.

Trade

Establishing distribution channels and initiating operations in the targeted countries for the implementation of deployed treatments.




	Case Numbers	Death	Treatment Status
AMB Resistance	~1 Billion people	>5,000,000 people/year	None
Sepsis	>50,000 people/year	>10 million people/year	Antibacterial (NVT)
Pneumonia	~400 million people/year	4-6 million people/year	Antibacterial
Tuberculosis	~30 million people/year	2 Million people/year	Antibacterial
HIV/AIDS	~40 million people	700 thousand people/year	Suppressor (NVT)
Hepatitis B	~400 million People	1.5 million people/year	Suppressor (NVT)
COVID19	Pandemic		NVT-(No Valid Treatment)

Treatment Area

In the short-term program, the treatment area is planned to focus on diseases with high mortality risk that either lack treatment or have no valid treatment, along with the ongoing risk of creating a pandemic with COVID-19. Clinical study plans have been formulated based on this strategy.


Road Map

3-year short-term foreseeable, pessimistic scenario.



Investment Budget

Budget Distribution Ratios



Working Capital

Budget: 8,750.000 USD

3 country office setup and other operating expenses.

Science Investment

Budget: 800.000 USD

Clinical study for 4 diseases

Technological Investment

Budget: 650.000 USD

Wearable Technology Investments
Cloud Investments

Total Budget : 10.200.000 USD

Numbers



These are the values included in the projection based on company valuation.

	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033
Number of Countries	3	5	10	20	30	40	50	60	70	80
Number of Medical Devices	521	1.227	4.287	8.565	18.064	31.952	50.401	71.132	94.942	120.805
Annual Number of Treatments	14.985	150.842	773.750	1.662.566	3.284.643	6.488.311	9.817.692	11.483.726	15.229.951	62.637.928
EBITDA	\$ -5.020.925,00	\$ 13.374.424,00	\$ 104.167.477,00	\$ 243.677.667,00	\$ 489.978.919,00	\$ 993.711.248,00	\$ 1.528.069.659,00	\$ 1.907.069.639,00	\$ 2.246.732.961,00	\$ 2.470.182.508,00
EBITDA Margin	-212%	56,10%	84,40%	89,30%	91,20%	94,00%	95,00%	95,20%	95,30%	95,30%
Net Cash	\$ -8.902.986,06	\$ 9.229.972,23	\$ 42.282.778,15	\$ 114.005.016,11	\$ 350.509.845,37	\$ 721.606.075,23	\$ 1.115.895.762,45	\$ 1.265.491.547,13	\$ 1.517.274.091,41	\$ 1.683.017.838,21

DCF	\$2.268.617.186,73
DCF Discount Rate	15%
IRR	304,75%
Company Valuation	\$85.831.855

Notes:

Based on treatment sales.

The patient share for only 6 diseases was taken as basis. The area of intense competition is isolated.

it is assumed that 1,003% of the world market will be reached within 10 years by assuming a constant population,

Revenues related to Covid19 and flu treatments are not taken into account.

The wearable technology return is not taken into account.

The Company valuation report was prepared by Bizim Menkul Değerler A.Ş. on 19.09.2023.

THANK YOU!



AVB
BIOTECH

AVBBIO.COM